185 related articles for article (PubMed ID: 31600558)
1. Safety of Intradetrusor OnabotulinumtoxinA (BTX-A) Injection in the Asymptomatic Patient With a Positive Urine Dip.
Derisavifard S; Giusto LL; Zahner P; Rueb JJ; Goldman HB
Urology; 2020 Jan; 135():38-43. PubMed ID: 31600558
[TBL] [Abstract][Full Text] [Related]
2. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
Chapple C; Sievert KD; MacDiarmid S; Khullar V; Radziszewski P; Nardo C; Thompson C; Zhou J; Haag-Molkenteller C
Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668
[TBL] [Abstract][Full Text] [Related]
3. OnabotulinumtoxinA for the Treatment of Patients with Overactive Bladder and Urinary Incontinence: Results of a Phase 3, Randomized, Placebo Controlled Trial.
Nitti VW; Dmochowski R; Herschorn S; Sand P; Thompson C; Nardo C; Yan X; Haag-Molkenteller C;
J Urol; 2017 Feb; 197(2S):S216-S223. PubMed ID: 28012773
[TBL] [Abstract][Full Text] [Related]
4. Predictors of Poor Response and Adverse Events Following Botulinum Toxin-A for Refractory Idiopathic Overactive Bladder.
Abrar M; Stroman L; Malde S; Solomon E; Sahai A
Urology; 2020 Jan; 135():32-37. PubMed ID: 31626856
[TBL] [Abstract][Full Text] [Related]
5. The therapeutic effects of repeated detrusor injections between 200 or 300 units of onabotulinumtoxinA in chronic spinal cord injured patients.
Chen YC; Kuo HC
Neurourol Urodyn; 2014 Jan; 33(1):129-34. PubMed ID: 23494629
[TBL] [Abstract][Full Text] [Related]
6. Preoperative urodynamic factors predicting outcome of botulinum toxin-A intradetrusor injection in children with neurogenic detrusor overactivity.
Kim SW; Choi JH; Lee YS; Han SW; Im YJ
Urology; 2014 Dec; 84(6):1480-4. PubMed ID: 25432842
[TBL] [Abstract][Full Text] [Related]
7. Prolonged urinary retention after intravesical botulinum injection for treatment of idiopathic detrusor overactivity.
King AB; Rapp DE
Can J Urol; 2011 Apr; 18(2):5657-9. PubMed ID: 21504656
[TBL] [Abstract][Full Text] [Related]
8. Bladder base/trigone injection is safe and as effective as bladder body injection of onabotulinumtoxinA for idiopathic detrusor overactivity refractory to antimuscarinics.
Kuo HC
Neurourol Urodyn; 2011 Sep; 30(7):1242-8. PubMed ID: 21560152
[TBL] [Abstract][Full Text] [Related]
9. Management of refractory idiopathic overactive bladder: intradetrusor injection of botulinum toxin type A versus posterior tibial nerve stimulation.
Sherif H; Khalil M; Omar R
Can J Urol; 2017 Jun; 24(3):8838-8846. PubMed ID: 28646940
[TBL] [Abstract][Full Text] [Related]
10. Pilot study evaluating the safety of intradetrusor injections of botulinum toxin type A: investigation of generalized spread using single-fiber EMG.
Schnitzler A; Genet F; Durand MC; Roche N; Bensmail D; Chartier-Kastler E; Denys P
Neurourol Urodyn; 2011 Nov; 30(8):1533-7. PubMed ID: 21661038
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of onabotulinumtoxinA injection in patients with refractory overactive bladder: First multicentric study in Turkish population.
Onem K; Bayrak O; Demirtas A; Coskun B; Dincer M; Kocak I; Onur R;
Neurourol Urodyn; 2018 Jan; 37(1):263-268. PubMed ID: 28407394
[TBL] [Abstract][Full Text] [Related]
12. Discontinuation rates and inter-injection interval for repeated intravesical botulinum toxin type A injections for detrusor overactivity.
Veeratterapillay R; Harding C; Teo L; Vasdev N; Abroaf A; Dorkin TJ; Pickard RS; Hasan T; Thorpe AC
Int J Urol; 2014 Feb; 21(2):175-8. PubMed ID: 23819724
[TBL] [Abstract][Full Text] [Related]
13. Predictive factors of adverse events after intravesical suburothelial onabotulinumtoxina injections for overactive bladder syndrome-A real-life practice of 290 cases in a single center.
Jiang YH; Ong HL; Kuo HC
Neurourol Urodyn; 2017 Jan; 36(1):142-147. PubMed ID: 26417884
[TBL] [Abstract][Full Text] [Related]
14. Adverse events of intravesical botulinum toxin a injections for idiopathic detrusor overactivity: risk factors and influence on treatment outcome.
Kuo HC; Liao CH; Chung SD
Eur Urol; 2010 Dec; 58(6):919-26. PubMed ID: 20864251
[TBL] [Abstract][Full Text] [Related]
15. Treatment Response and Complications after Intradetrusor OnabotulinumtoxinA Injection in Male Patients with Idiopathic Overactive Bladder Syndrome.
Mateu Arrom L; Mayordomo Ferrer O; Sabiote Rubio L; Gutierrez Ruiz C; Martínez Barea V; Palou Redorta J; Errando Smet C
J Urol; 2020 Feb; 203(2):392-397. PubMed ID: 31479408
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial.
Cruz F; Herschorn S; Aliotta P; Brin M; Thompson C; Lam W; Daniell G; Heesakkers J; Haag-Molkenteller C
Eur Urol; 2011 Oct; 60(4):742-50. PubMed ID: 21798658
[TBL] [Abstract][Full Text] [Related]
17. Urinary retention rates after intravesical onabotulinumtoxinA injection for idiopathic overactive bladder in clinical practice and predictors of this outcome.
Osborn DJ; Kaufman MR; Mock S; Guan MJ; Dmochowski RR; Reynolds WS
Neurourol Urodyn; 2015 Sep; 34(7):675-8. PubMed ID: 24975819
[TBL] [Abstract][Full Text] [Related]
18. Switch to Abobotulinum toxin A may be useful in the treatment of neurogenic detrusor overactivity when intradetrusor injections of Onabotulinum toxin A failed.
Bottet F; Peyronnet B; Boissier R; Reiss B; Previnaire JG; Manunta A; Kerdraon J; Ruffion A; Lenormand L; Perrouin Verbe B; Gaillet S; Gamé X; Karsenty G;
Neurourol Urodyn; 2018 Jan; 37(1):291-297. PubMed ID: 28431196
[TBL] [Abstract][Full Text] [Related]
19. Less is more-A pilot study evaluating one to three intradetrusor sites for injection of OnabotulinumtoxinA for neurogenic and idiopathic detrusor overactivity.
Avallone MA; Sack BS; El-Arabi A; Guralnick ML; O'Connor RC
Neurourol Urodyn; 2017 Apr; 36(4):1104-1107. PubMed ID: 27283922
[TBL] [Abstract][Full Text] [Related]
20. Two-Year Outcomes of Sacral Neuromodulation Versus OnabotulinumtoxinA for Refractory Urgency Urinary Incontinence: A Randomized Trial.
Amundsen CL; Komesu YM; Chermansky C; Gregory WT; Myers DL; Honeycutt EF; Vasavada SP; Nguyen JN; Wilson TS; Harvie HS; Wallace D;
Eur Urol; 2018 Jul; 74(1):66-73. PubMed ID: 29482936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
